Abstract:Background and purposePromoting energy metabolism is known to provide therapeutic effects for obesity and associated metabolic disorders. The present study evaluated the therapeutic effects of the newly identified bouchardatine (Bou) on obesity‐associated metabolic disorders and the molecular mechanisms of these effects.Experimental approachThe molecular mode of action of Bou for its effects on lipid metabolism was first examined in 3T3‐L1 adipocytes and HepG2 cells. This was followed by an evaluation of its metabolic effects in mice fed a high‐fat diet for 16 weeks with Bou being administered in the last 5 weeks. Further mechanistic investigations were conducted in pertinent organs of the mice and relevant cell models.Key resultsIn 3T3‐L1 adipocytes, Bou reduced lipid content and increased sirtuin 1 (SIRT1) activity to facilitate liver kinase B1 (LKB1) activation of AMPK. Chronic administration of Bou (50 mg∙kg−1 every other day) in mice significantly attenuated high‐fat diet‐induced increases in body weight gain, dyslipidaemia and fatty liver without affecting food intake and no adverse effects were detected. These metabolic effects were associated with activation of the SIRT1–LKB1–AMPK signalling pathway in adipose tissue and liver. Of particular note, UCP1 expression and mitochondrial biogenesis were increased in both white and brown adipose tissues of Bou‐treated mice. Incubation with Bou induced similar changes in primary brown adipocytes isolated from mice.Conclusions and implicationsBou may have therapeutic potential for obesity‐related metabolic diseases by increasing the capacity of energy expenditure in adipose tissues and liver through a mechanism involving the SIRT1–LKB1–AMPK axis.

Design, Synthesis and Biological Evaluation of Novel Bouchardatine Analogs As Potential Inhibitors of Adipogenesis/lipogenesis in 3T3-L1 Adipocytes

Novel Bouchardatine Analogs as Potential Inhibitors of Adipogenesis / Lipogenesis in 3 T 3L 1 adipocytes

Synthesis and Biological Evaluation of Novel Bouchardatine Derivatives As Potential Adipogenesis/Lipogenesis Inhibitors for Antiobesity Treatment

Discovery of Natural Alkaloid Bouchardatine As A Novel Inhibitor of Adipogenesis/Lipogenesis in 3T3-L1 Adipocytes

Natural Alkaloid Bouchardatine Ameliorates Metabolic Disorders in High-Fat Diet-Fed Mice by Stimulating the Sirtuin 1/liver Kinase B-1/Ampk Axis

Design, Synthesis and Biological Evaluation of N,N-3-phenyl-3-benzylaminopropanamide Derivatives As Novel Cholesteryl Ester Transfer Protein Inhibitor

Discovery of Novel N,N-3-phenyl-3-benzylaminopropionanilides As Potent Inhibitors of Cholesteryl Ester Transfer Protein in Vivo.

Synthesis and biological activity of novel barbituric and thiobarbituric acid derivatives against non-alcoholic fatty liver disease

Development of Novel N -Acylhydrazone Derivatives with High Anti-obesity Activity and Improved Safety by Exploring the Pharmaceutical Properties of Aldehyde Group

Synthesis and Lipid-Lowering Evaluation of 3-Methyl-1h-purine-2,6-dione Derivatives As Potent and Orally Available Anti-Obesity Agents.

Lipid Accumulation Inhibitory Activities of Novel Isoxazole-Based Chenodeoxycholic Acids: Design, Synthesis and Preliminary Mechanism Study

Synthesis and biological evaluation of 3-methyl-5-phenylthieno[2,3-d]pyrimidine-2,4(1H,3H)-dione derivatives for the treatment of diet-induced obesity.

Design, synthesis and evaluation of 2-pyrimidinylindole derivatives as anti-obesity agents by regulating lipid metabolism

Design, synthesis and structure-activity relationship of novel 2-pyrimidinylindole derivatives as orally available anti-obesity agents

Design, synthesis and biological evaluation of new 1,ω-Bis-(5-alkyl-3-tosyl-1,3,4,2-triazaphospholino)alkanes as in vitro α-amylase and lipase inhibitors

Discovery of C-9 Modified Berberine Derivatives as Novel Lipid-Lowering Agents

From Hit to Lead: Structure-based Discovery of Naphthalene-1-sulfonamide Derivatives As Potent and Selective Inhibitors of Fatty Acid Binding Protein 4.

Structure-Based Optimization and Biological Evaluation of Pancreatic Lipase Inhibitors As Novel Potential Antiobesity Agents

Design, synthesis and biological evaluation of novel chalcone-like compounds as potent and reversible pancreatic lipase inhibitors

Oleanolic Acid Derivative HA-20 Inhibits Adipogenesis in a Manner Involving PPARγ-FABP4/aP2 Pathway.

Design, synthesis, and biological activity of 9-O-cinnamoylberberines as novel lipid-lowering agents